摘要
制备丹参酮IIA纳米球,以用于观察局部灌注后对损伤血管内膜增殖的抑制。通过超声乳化法制备了PLGA包载的、载药量为1.55%±0.016%(mg/mg),平均粒径为119nm的丹参酮IIA纳米球,将其和空白纳米粒分别局部灌注于球囊损伤后的兔颈动脉内,对内膜增殖的情况进行分析。结果发现:28d丹参酮IIA纳米粒组与空白纳米粒组和动脉损伤模型组相比,内膜面积明显减少(P<0.01);空白纳米粒组与模型组的内膜面积比较,无明显变化(P=0.302);内膜面积/中膜面积作为内膜增殖指数的指标,丹参酮IIA纳米粒组比动脉损伤模型组减少了39.7%。本实验成功地研制了丹参酮IIA纳米粒,局部灌注于内膜剥脱后的血管内,不仅证实了其组织相容性,而且显示出良好的局部摄取,以及显著抑制损伤血管内膜增殖的效应。
Tanshinone ⅡA nanoparticles were constructed and perfused in rabbit＇s right carotid after intimal denudation with ballon. Localization and retention at different time points of the coumarin-labeled drug nanoparticles were evaluated under laser confocal microscope. Nanoparticles were seen in the three layers of the cross-section artery. At 7 clays, they were mainly deposited in the medial layer, while the deposition was generally observed in the adventitia and media at 14 days and 28 days. In the Tanshinone ⅡA nanoparticle study, a significant reduction of the neo-intimal hyperplasia was noted by comparing the intimal area and the intima-media ratio in the three groups. And the PLGA nanoparticles appeared to be fully biocompatible. As a result, the local administration of the nanoparticles with incorporated Tanshinone ⅡA showed not only the preventive effects, but aslo the high absorption and good biocompatability in the whole arterial wall.
出处
《生物医学工程学杂志》
EI
CAS
CSCD
北大核心
2007年第4期812-816,共5页
Journal of Biomedical Engineering
基金
四川省科技厅应用基础研究资助项目(04JY029-079-1)
